Giredestrant

News

Roche delivers its data reveal for adjuvant giredestrant

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

News

Roche extols 'unprecedented' result with breast cancer drug

Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.

News

ESMO: Clear air emerges between Roche SERD and its rivals

Has Roche taken a lead in the oral SERD category of breast cancer therapies with data showing activity in wild-type ESR1 patients?

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

Roche's oral SERD giredestrant fails breast cancer trial

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme

Roche delivers its data reveal for adjuvant giredestrant

Roche extols 'unprecedented' result with breast cancer drug

ESMO: Clear air emerges between Roche SERD and its rivals

Roche's oral SERD comes good in 2nd-line breast cancer trial

Data cues up AZ oral SERD filing in first-line breast cancer

Roche's oral SERD giredestrant fails breast cancer trial

Kyverna rises on stiff person syndrome data

How to meet your physicians where they are online

Giredestrant

Editor's Picks